Skip to main content
LISATA THERAPEUTICS, INC. logo

LISATA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LSTA ISIN · US1280583022 LEI · 5493002287F62M3EGQ04 US Manufacturing
Open in API
Filings indexed 1,093 across all filing types
Latest filing 2014-04-25 Director's Dealing
Country US United States of America
Listing US LSTA

About LISATA THERAPEUTICS, INC.

https://www.lisata.com/

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other major diseases. The company's core technology is the proprietary CendR Platform®, designed to enhance the targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors. The platform also aims to target non-cancerous, immunosuppressive cells within the tumor microenvironment, seeking to improve the efficacy of a patient's immune system and immunotherapies in fighting cancer.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2014-04-25 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by NeoStem, Inc. It includes a slide presentation as Exhibit 99.1 dated April 2014. The text explicitly states that the slide presentation is intended for distribution to the investment community and at conferences, and it is accessible on the company's website. The document is short (4274 characters) and primarily serves to furnish the presentation rather than being a full financial report or earnings release. The presentation is described as a slide deck, which aligns with an Investor Presentation. The document also clarifies that the information is not "filed" for certain regulatory purposes, indicating it is supplementary material. Therefore, the best classification is Investor Presentation (IP).
2014-04-18 English
8-K
M&A Activity Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The text describes a merger agreement between NeoStem, Inc. and California Stem Cell, Inc., detailing the terms of the merger, consideration, escrow arrangements, indemnification, and milestone payments. This is a clear announcement of a merger transaction and related agreements, not a full annual or quarterly report, audit report, or earnings release. It is not a proxy statement or voting results announcement. The document is substantive and detailed, consistent with a merger activity filing. Therefore, the appropriate classification is 'M&A Activity' (Code: TAR).
2014-04-14 English
OWNERSHIP DOCUMENT
Director's Dealing
2014-04-11 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated April 11, 2014, by NeoStem, Inc. It announces a press release about a conference call scheduled for April 14, 2014. The content primarily describes the announcement of the conference call and webcast, including access details, and contains forward-looking statements disclaimers. There are no financial statements or substantive financial data included in the text. The document is short (4312 characters) and serves as a notification of an event rather than a full transcript or detailed report. Given these characteristics, this document fits best as a Regulatory Filing (RNS), which is a general regulatory announcement and a fallback category for filings that do not fit other specific categories. It is not a Call Transcript (CT) because it does not contain the full text of the call, only an announcement of it.
2014-04-11 English
OWNERSHIP DOCUMENT
Director's Dealing
2014-03-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.